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Introduction 
Malaria is the most infectious and dangerous disease in the world. 
The World Health Organization (WHO) estimated 225 million 
malaria cases worldwide with 781,000 deaths due to Plasmodium 
infection per year. Four types of  Plasmodium species (P. falcipa-
rum, P. vivax, P. malariae, and P. ovale) are responsible for almost 
all human infections. Plasmodium falciparum malaria is responsible 
for more than one million deaths that occur each year from ma-
laria infection in Africa. Most of  these deaths occur as a result of  
complications such as severe malaria associated anaemia (SMA) 
and cerebral malaria (CM) or coma [3]. Compliment Receptor 1 
(CR1), a protein on RBC cells that having role in immune com-
plex clearance. It’s also known as C3b/C4b receptor or CD35. In 
humans this protein is encoded by CR1 gene is located at on the 
long arm of  chromosome 1 at band 32 (1q32) and lies within a 
complex of  immunoregulatory genes. The Compliment Receptor 
1 (CR1) gene polymorphism conform density of  CD35 on RBC 
cells. The human CR1 binds to a major malarial adhesin, the P. 
falciparum erythrocyte membrane protein-one (PfEMP-1). High 
density of  CR1 on erythrocyte indicates high risk of  falciparum 
infection [1, 30, 48, 8].
Prevalence and Epidemiology of  p. falciparum
Malaria affects the 300-500 million people each year in which 1-3 
million people leading cause of  death worldwide annually. There 
are five Plasmodium species that infect humans; Plasmodium falci-
parum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae and 
Plasmodium knowlesi. These species differ in their morphology, im-
munology, and geographic distribution. Among the five species 
that cause malaria in humans, Plasmodium falciparum (P. falciparum) 
is the most virulent resulting in the greatest number of  complica-
tions and the great majority of  malaria-related deaths in children 
under the age of  five. The evolutionary history and geographical 
distribution of  P. falciparum reflects a three-way interaction be-
tween the parasite, the host, and the Anopheles sp. mosquito (the 
vector for transmission). Circa 1900, prior to the widespread use 
of  anti-malarials, the distribution of  malaria reached the geo-
graphic latitudes of  64º north and 32º south [45, 17].
However, genetic history and the co-evolution of  P. falciparum 
with humans suggest this has not always been the geographic 
model. The closest relative to the modern day P. falciparum is the 
chimpanzee malaria parasite, Plasmodium reichenowi. It has been ar-
gued that P. falciparum is of  African origin because P. reichenowi is 
a parasite that infects African chimpanzees. Despite some con-
troversy, it is generally accepted that the divergence of  these two 
species of  malaria occurred approximately 9-10 million years ago, 
prior to the divergence of  humans from non-human primate rela-
tives such as the chimpanzees. It is believed that the major spread 
of  P. falciparum in Africa occurred during the “Agrarian Revolution” 
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(4000-5000 years ago) when small nomadic groups began to es-
tablish larger settled communities; this lifestyle change provided 
ideal conditions for sustained P. falciparum transmission [18, 4]
(Figure 1).
Life Cycle of  Plasmodium Falciparum Malaria
The P. falciparum infection begins when a human host is bitten by 
an infected female Anopheles mosquito, and the mosquito injects 
sporozoites into the subcutaneous tissue of  the human host. The 
sporozoites, within one hour reach to the liver and infect hepato-
cytes. The duration of  the asymptomatic liver (exo-erythrocytic 
cycle) stage of  the infection is approximately one-two weeks. 
During this stage, each sporozoite may yield thousands of  mero-
zoites [14].
Invasion: The hepatocytes rupture releasing the merozoites into 
the blood stream (the beginning of  clinical disease) where they are 
able to enter into RBCs by a complex invasion process comprised 
of  four phases: (a) initial recognition and reversible attachment of  
the merozoite to the RBC membrane. (b) reorientation. (c) invagi-
nation of  the RBC membrane around the merozoite. (d) resealing 
of  the RBC membrane after completion of  merozoite invasion. 
RBC invasion is a rapid process that is governed by molecular 
interactions between the merozoites and the host cell surface [2, 
31].
Primary contact is initiated by a surface coat of  proteins that 
is largely comprised of  glycosylphosphatidylinositol (GPI)-an-
chored membrane proteins. There are at least nine recognized 
GPI anchored proteins that are predicted to be potential RBC 
ligands. Merozoite surface protein-1 (MSP-1) is the dominant an-
tigen and is essential for parasite survival. MSP-1 is involved in 
the initial recognition of  the RBC via sialic acid residues found 
on the RBC membrane. Other important proteins are MSP-2, -3 
and -4. P. falciparum apical membrane antigen-1 (PfAMA-1) is also 
essential for successful invasion as it is translocated to the mero-
zoites surface before invasion of  the RBCs, and is also present 
on the sporozoite for invasion into hepatocytes [43, 2] (Figure 2).
Maturation: Initially, the merozoites develop into an early tropho-
zoite stage known as the “ring form”. The ring form persists for 
24 hours and matures inside the RBC through a highly active met-
abolic state. The P. falciparum ring feeds from the host cytoplasm, 
importing glucose and breaking down hemoglobin into constitu-
ent amino acids. Following the ring stage, P. falciparum matures 
and develops to a late stage trophozite. The mature trophozoite 
stage parasite replicates by nuclear division resulting in schizont 
stage parasites. Each schizont is comprised of  20-24 merozoites, 
which are released upon rupture of  the infected RBC. When the 
infected RBCs rupture, merozoites and parasite metabolic waste 
Figure 1. Geographic distribution of  Plasmodium falciparum malaria [44].
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Figure 2. Life cycle of  Plasmodium falciparum malaria [3].
Sporozoites Merozoite
Infection
Transmission 
to mosquito
Liver
Merozoite
A sexual 
cycle
Gemotocytes
Merozoite
invasion
Adhesion in 
placenta
Infected 
RBC
Infected 
RBC
Red Cell
endothelium
Adhesion to 
endothelium
Saket RD et al., (2015) Compliment Receptor Type - 1 (CD35) Gene Polymorphism and Plasmodium Falciperum Malaria. Int J Med Biotechnol Genetics. 03(3), 27-33
29
http://scidoc.org/IJMBG.php
products such as hemozoin, degradation of  hemoglobin, and 
parasite toxins are released. The majority of  the merozoites will 
invade other RBCs continuing the asexual cycle; however, some 
parasites will form sexual stage forms called gametocytes which 
are then transmitted to new hosts by the Anopheles vector [31, 2, 
5, 43, 45, 11, 32].
Pathophysiology of  Plasmodium Falciparum Malaria
Infection with P. falciparum results in considerable morbidity and 
without treatment may be fatal. The clinical outcome of  malaria 
depends on many contributing factors including the parasite’s 
virulence, the host’s response, geographical, and socio-economic 
factors (Table 1) [31]. The combination of  these factors result in a 
range of  possible outcomes for the host, including asymptomatic 
infection, uncomplicated malaria infection, severe infection (se-
vere malaria anemia and cerebral malaria) and death.
Clinical stages of  Malaria Pathogenesis: There are three 
defined clinical stages of  malaria pathogenesis: uncomplicated 
malaria, severe malaria, and cerebral malaria. Uncomplicated ma-
laria initially presents with fever and chills, nausea and headache, 
sometimes associated with diarrhea and vomiting. Unfortunately, 
because of  the similarity in symptoms, malarial infection is often 
mistaken for many other infections including influenza or gastro-
intestinal infection and is therefore not properly treated [43]. In 
1990, the World Health Organization (WHO) established crite-
ria for the diagnosis of  severe malaria. The major criteria include 
neurological involvement (cerebral malaria), pulmonary edema, 
acute renal failure, and severe anemia. Severe anemia is the second 
most common symptom of  P. falciparum infection and is caused 
by the destruction of  RBCs and overall decreased erythropoiesis. 
Acidosis and hypoglycemia are the most common metabolic com-
plications [48, 51].
Table 1. Factors contributing to the clinical outcome of  P. falciparum infection [Adapted from [31]].
Parasite Factors Host Factors Geographic and Social factors
-Drug Resistance
-Multiplication rate
-Invasion Pathways
-Cytoadherence
-Rosetting
-Malaria toxins (hemo-
zoin)
-Antigenic Variation 
(PfEMP1)
Immunity
-Genetics : Sickle cell, thalassae-
mia, ABO blood type (?) etc.
-Age
-Pregnancy
-Pro-inflammatory cytokines
-Transmission intensity
-Culture and economic factors
-Access to treatment
DeathClinical OutcomeAsymptomatic
Cerebral malaria is the most common cause of  death in adults 
and children with severe malaria. According to the WHO, the 
strict definition of  cerebral malaria requires the presence of  P. fal-
ciparum parasitemia and unarousable coma with a Glasgow Coma 
score of  9 or less; all other causes of  coma, such as hypoglycemia, 
bacterial meningitis and viral encephalitis, need to be excluded. 
Typical neurological symptoms include coma, seizures, edema, 
and brainstem damage. Engorgement of  cerebral capillaries and 
venules filled with infected RBCs and non-infected RBCs are typi-
cal histopathological findings in cerebral malaria. As the infec-
tion progresses, the increasingly detrimental pathogenesis of  P. 
falciparum malaria is believed to be caused by two main factors: (a) 
an imbalance of  cytokine production; and (b) the sequestration 
of  infected RBCs in the microvasculature of  vital organs [37, 19].
Inflammatory Response: P. falciparum infection results in an in-
crease of  both pro-inflammatory cytokines and anti-inflammato-
ry cytokines. However, in cerebral malaria, there is an unbalanced 
and excessive production of  the pro-inflammatory response. 
Blood concentrations of  pro-inflammatory cytokines, especially 
tumor necrosis factor (TNF), interferon gamma (IFN-γ), and IL-
6, have been shown to be raised in cerebral malaria. TNF may 
contribute to malaria pathogenesis including cerebral malaria. 
TNF up regulates endothelial cytoadherence receptors such as 
intercellular adhesion molecule-1 (ICAM-1), vascular cell adhe-
sion molecule-1 (VCAM-1), and E-selectin. TNF may cause hy-
poglycemia and dyserthryopoesis, and has been shown to induce 
the release of  nitric oxide (NO) which interferes with synaptic 
transmission [10, 21].
Parasite Sequestration: P. falciparum has a unique ability to ad-
here to host micro vasculature endothelium, a process known as 
sequestration. Sequestration causes micro vascular obstruction 
and compromises the blood flow through tissues such as the liver, 
spleen, lung, and brain. The effects of  sequestration include me-
chanical obstruction (which can lead to hypoxia), metabolic dis-
turbances and is a central point where parasite toxins and inflam-
matory mediators concentrate [47] (Figure 3).
Increased expression of  cytoadherence receptors enhances in-
fected RBC sequestration to the endothelium via parasite derived 
proteins (expressed on the surface of  the infected RBC), such as 
PfEMP-1. The principal parasite surface protein and sequestra-
tion ligand known as P. falciparum erythrocyte membrane protein 
1 (PfEMP-1), encoded by var genes, is expressed. It is predomi-
nantly mature stage parasites (trophozoites and schizonts) that 
adhere to the microvasculature [16].
The PfEMP-1 molecule has a pivotal role in the pathogenesis of  
P. falciparum as a number of  host receptors are recognized by the 
various extracellular binding domains of  PfEMP-1. Thus permit-
ting the infected RBCs to adhere with host endothelium. In the 
case of  cerebral malaria, PfEMP-1 may mediate adhesion to sev-
eral adhesion molecules, in particular ICAM-1 which is unregu-
lated on the cerebral vascular endothelium [6].
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Innate immunity to P. falciparum malaria: The innate immune 
response is crucial to the outcome during a P .falciparum infection. 
Innate immune responses take effect immediately and provide 
an early defence until the adaptive immune response is engaged. 
In some cases, an infection by P. falciparum may be controlled by 
the innate immune system. 61 Parasite burdens observed in non-
immune individuals with acute P. falciparum malaria are lower than 
expected based on parasite replication rates observed in vitro, 
suggesting that the innate immune system can contribute to ef-
fective control of  acute parasite replication before the adaptive 
immune response develops [34].
The innate immune system functions to limit the maximum para-
site density, but gradually acquired adaptive mechanisms complete 
parasite elimination. The innate immune system is essential for 
most inflammatory responses that are triggered by monocytic 
cells, other leukocytes and mast cells through their innate sens-
ing receptors. Macrophages are important in innate immunity as 
they are able to clear parasitized RBCs in the absence of  opsoniz-
ing malaria-specific antibodies. It is hypothesized that there are 
two methods of  infected RBC uptake by macrophages. The pre-
dominant method of  uptake involves the binding of  non-specific 
IgG and complement to the surface of  infected RBCs, and in-
creased exposure of  senescent RBC markers such as exposure 
of  phosphatidylserine (PS). This method induces the release of  
pro-inflammatory cytokines. The second method of  uptake is 
CD36 mediated, which involves the binding of  CD36 on the mac-
rophage to PfEMP-1 on the infected RBCs. This method does 
not involve the release of  pro-inflammatory cytokines [42, 20].
There are three main biochemical pathways that result in activa-
tion of  the complement system: the classical complement binding 
pathway; the mannose-binding lectin pathway; and the alternative 
pathway. All three lead to the formation of  C3 and C5 convertase 
which results in the cleavage of  C3 and C5 into C3a, C3b, C5a and 
C5b, respectively. RBCs opsonized by IgG and complement (C3b) 
are recognized by the Fc receptor (FcR) and CR1 (respectively), 
and phagocytosed by macrophages. This method of  clearance is 
effective in senescent and damaged RBCs, and also in P. falciparum 
infected RBCs [15].
Complement Receptor Type - 1 (CD35)
CR1 is a 200-kDa single chain membrane bound glycoprotein 
and a member of  the regulators of  complement activation (RCA) 
gene cluster. CR1 possesses complex tri and tetra N-linked oli-
gosaccharides in its mature form and the gene for this protein 
is located on the q32 arm of  chromosome 1. It is composed of  
a number of  repeated domains called short consensus repeats 
(SCRs) each of  which is composed of  60 amino acids containing 
four invariant cysteines. The extracellular domain of  the CR1 is 
composed of  30 SCRs, the first 28 of  which are arranged in tan-
dem repeats in homologous groups of  7, with each group known 
as long homologous repeat (LHR). SCRs 8-12 and SCRs 15-18 
preferentially bind to C3b and SCRs 1-4 preferentially bind to 
C4b. The region of  CR1 that interacts with infected erythrocytes 
to form rosettes has been mapped to LHRB and first three SCRs 
of  LHR-C, SCR 10 and 17 have been particularly found to play an 
important role in this interaction [23, 22].
Effect of  differential CR1 expression on malarial patho-
genesis: Differences in the expression of  CR1 on erythrocytes 
might determine susceptibility of  an individual towards develop-
ment of  cerebral malaria and severe malaria-associated anemia. In 
one of  the studies it was suggested that young children may be 
more susceptible to SMA because of  their lower levels of  RBC 
complement regulatory proteins, which make them less equipped 
to handle IC formation and complement activation. Previously 
same group of  researchers had proved that a decline in levels of  
CR1 and increase in immune complex levels significantly associ-
ates with SMA. The mechanism for the loss of  CR1 from the 
surface of  erythrocytes is being investigated. A series of  experi-
ments indicated that CR1 present in the form of  clusters on RBC 
surface, undergoes unclustering due to the binding of  IgM -C3b 
complexes to glycophorin A. Unclustering might promote rapid 
loss of  CR1 from the surface of  erythrocytes infected with the 
malaria parasite [7].
CR1 polymorphisms: CR1 is a highly polymorphic glycoprotein. 
Three different polymorphic forms of  CR1 have been identified, 
namely structural (size variation 160-250 kDa), density (high and 
low expression on RBCs controlled by alleles H and L) and knops 
blood group (McC (a+)/McC (b+); Sl (a+)/Sl (a-); Kna/ Knb).
Structural polymorphism: Four different structural polymor-
phic forms of  CR1 are known, namely A, B, C and D (CR1*1, 
CR1*2, CR1*3, CR1*4) with respective molecular weights of  
190, 220, 160 and 250 kDa (under non-reducing conditions). This 
polymorphism is regulated by four autosomal co-dominant al-
leles. A polymorphism in the CR1 transcripts with incremental 
differences of  1.4 kb in mRNA was present in donors expressing 
the various polymorphic forms. This difference corresponds to 
the size of  one LHR and 40 kDa difference, seen among allo-
typic forms of  CR1. Therefore on the basis of  this observation 
it was suggested that the insertion or deletion forms the basis of  
structural polymorphism. Analysis of  restriction fragment length 
polymorphism (RFLP) suggested that intragenic duplication rath-
er than alternate mRNA splicing is responsible for the allotypic 
differences [24, 12].
Figure 3. The PfEMP-1 molecule and associated host receptors [Adapted from [7]].
A,B antigen   CD36   ICMA-1        CSA
HS                 CD31   CD31                        HostReceptors
CRI                IgM
DBL-1α CIDR1α DBL-2β C2 DBL-3γ DBL-4ε DBL-5δ CIDR1β ATS
Extracellular Domain
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Density polymorphism: Second type of  polymorphism is a 
Hind III RFLP, which in Caucasians but not in Africans, cor-
relates with CR1 copy number on erythrocytes. Homozygotes 
for the L (low expression) allele usually express fewer than 200 
copies of  CR1, homozygotes for the H (high expression) allele 
express several times this number and heterozygotes are interme-
diate. This polymorphism arises due to a single base change in the 
intron of  d1d2 segment within the LHR-D (Long homologous 
repeat) region resulting in the generation of  a polymorphic Hind 
III site within this region [8].
Genotypic frequencies of  HH, HL and LL forms have also been 
studied in the malaria endemic and non-endemic groups in differ-
ent populations. In nonendemic Caucasian and Choctaw popula-
tion groups in USA, the gene frequencies for H and L alleles were 
found to be 0.82, 0.18 and 0.84, 0.16 respectively. In endemic 
Black Africans the gene frequencies for H and L alleles were 0.85 
and 0.15; in S. Chinese-Taiwanese 0.71 and 0.29; in Pacific Asians 
0.42 and 0.58 and in Cambodians 0.53 and 0.47 respectively [48].
Knops polymorphism: The third type of  polymorphism repre-
sented by Knops blood group system is of  particular interest. In 
this system, Mca and Mcb is one allelic antigen pair and Sla and 
Vil is another pair. The corresponding phenotypes for the fi rst 
pair are McC (a+) and McC (b+) and for the second pair are Sl (a+) 
and Sl (a-). Studies have now established the molecular basis for 
Knops polymorphism. These antigens have been localized on the 
LHR-D segment of  CR1. Single nucleotide polymorphisms oc-
curring in SCR 25, which lead to amino acid substitutions, result 
in generation of  these polymorphic forms Population based stud-
ies have been carried out to determine the distribution of  differ-
ent types of  Knops polymorphic forms in different populations. 
The gene frequencies for Sl (a+) and Sl (a-) in African American 
persons are almost equal (0.48 vs. 0.52) wheras Sl (a-) is greatly 
increased in Africa [25, 33].
Out of  the three polymorphic forms, size polymorphism has not 
been found to play a role in determining susceptibility to severe 
malaria. With regard to density polymorphism, some studies sug-
gest that low-density allele confers protection against malaria, 
whereas another suggested that low- density allele might be a risk 
factor for severe forms of  malaria. Erythrocytes with low CR1 ex-
pression (because of  the homozygous LL genotype of  CR1) have 
been shown to form reduced number of  rosettes with Plasmodium 
falciparum infected cells [40, 36, 9].
Cytokines and Malarial Infection
The study of  characteristics of  immune responses against Plasmo-
dium is based on murine experimental systems. Both, cell mediated 
and antibody-dependent immunity are required for adequate pro-
tection, likely encompassing different mechanisms finely tuned in 
time. Besides, innate immunity is thought to play a crucial role 
in clearing Plasmodium from parasitized hosts [34]. In splenic re-
sponse, tissular changes that provoke alterations in blood flow 
through the organ. These changes prevent the access of  infected 
erythrocytes to splenic tissues in which the immune response 
is going on until armed effector cells are produced. In general, 
most of  the evidence supports the hypothesis that cells from the 
monocyte-macrophage lineage are more effective than neutro-
phils at phagocytosing parasitized erythrocytes [52].
Recent work has shown that P. chabaudi infection in ᵞ/ᵟ T-cell-
deficient mice have exacerbated early and chronic parasitemias. 
These results would fit well with data ascribing early production 
of  gamma interferon (IFN-γ) and tumor necrosis factor alpha 
(TNF-α) both to spleenic ᵞ/ᵟ T lymphocytes and to natural killer 
(NK) cells [53, 41]. Both the cellular and humoral responses are 
pivotal elements in the eradication of  Plasmodium from the body, 
and both are critically dependent on ᵞ/ᵟ CD4+ lymphocytes. It 
has been firmly established that CD4+ T cells are comprised of  
at least two functionally different subsets, distinguished on the 
basis of  lymphokine secretion in Th1 (IFN-γ-producing) and Th2 
(interleukin-4 [IL-4]/IL-5-producing) cells. CD4+ T cells of  either 
Th1 or Th2 type also have regulatory functions in human P. falci-
parum malaria. Both Th1 and Th2 responses seem to be required 
to control the infection, but they need to be adequately tuned in 
intensity and time [26, 49].
Cytokines in Early Protection: The early production of  IFN-γ 
to give resistance against infection. In support of  this view, analy-
sis of  IFN-γ R-/- mice infected with P. chabaudi reveals a critical 
role of  IFN-γ in immunity against this pathogen, although the 
production of  parasite-specific immunoglobulins was not af-
fected [Favre, N., et. al. 1997]. Interestingly, Tan et. al. reported 
that IFN responsive factor (IRF-1)-/- mice infected with P. berghei 
showed lower mortality than wild-type mice, although they pro-
duced no IFN-γ or NO [50].
It is likely that there are mechanisms of  resistance independ-
ent of  IFN- γ and NO. In this regard, it is interesting that treat-
ment in vivo with anti-IFN-γ exacerbates P. yoelii 17XL infection 
in C57BL/6 because mice treated with antibody die earlier. In 
contrast, treatment with aminoguanidine, an irreversible inhibi-
tor of  NO production, has no effect. Consistently, mice lacking 
inducible nitric oxide synthase (iNOS-/-) cleared P. berghei XAT (an 
attenuated variant of  P. berghei NK65) as effectively as did wild-
type animals. In this case, resistance was dependent on IFN- γ, 
since it’s in vivo, blocking provoked progression of  parasitemia 
and death [53]. 
The overall conclusion that can be drawn from this is that the 
role of  a particular cytokine is likely to be different at different 
stages of  the infectious process. A prominent role in switching 
from Th1 to Th2 responses is attributed to IL-10. Therefore, it is 
probably involved in controlling the adequate timing of  antipara-
sitic responses. Early IL-10 production has been associated with 
susceptibility to infection, and it is thought that this cytokine has 
a prominent anti-inflammatory effect, limiting in some way the 
damage inflicted on normal tissues by an excessive Th1 response 
[27, 54].
Cytokines in the Diagnosis of  Malaria: The Th2 profiles have 
been reported in humans, with elevated levels of  IgE being found 
in the blood of  malaria patients, presumably due to the predomi-
nance of  Th2 cells over Th1 helper cells. This polarization was 
significantly higher in the case of  patients suffering from severe 
malaria [39]. Th1 responses are important for clearance of  P. fal-
ciparum malaria. Non-immune children with severe P. falciparum 
malaria showed lower levels of  IL-12 and IFN-γ in serum and 
had a reduced capacity to produce them after in vitro stimulation. 
It is interesting that children with severe anemia had the highest 
levels of  TNF-γ [28]. Furthermore, Luty et al. [29] found that 
peripheral blood mononuclear cells of  patients with mild malaria 
produced IFN-γ in response to malarial antigens, whereas those 
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with severe malaria did not. The studies on Ghanaian children 
showed that only patients with uncomplicated malaria had a posi-
tive correlation with levels of  TNF- α and soluble TNF- α R1 and 
TNF- α R2 in serum. In the same study, children with CM had 
high levels of  TNF- α, and although TNF- α level were associ-
ated with fever no differences were observed in soluble TNF- α 
receptors. Interestingly, children with fever and detectable para-
sitemia, but not afebrile parasitized patients, had elevated levels of  
TNF- α [35]. In this regard, patients who died from P. falciparum 
malaria had higher amounts of  IL-6, IL-10, and TNF- α in serum 
than did the patients who survived. In the present study, IL-6, IL-
10, and IFN- γ were associated with hyperparasitemia, jaundice, 
and shock. Moreover, TNF- α was associated with renal failure. 
Surprisingly, lower levels of  cytokines were found in CM. In an 
important finding, a relative deficiency of  IL-10 was detected as 
death approached [10].
Conclusion
Malaria is a worldwide spreaded disease due to plasmodium spe-
cies (P. falciparum, P. vivax, P. malariae and P. ovale). It affects 300-
500 million people in which 1-3 million going to death. All of  
plasmodium species, P. falciparum is very dangerous leads to cer-
ebral malaria. For completing, his life cycle, plasmodium having 
two host first mosquito (as a vector) and second human. When 
plasmodium is introduced in blood by mosquito, it attached with 
RBCs through CD35 (CR1) which act as a receptor for PfEMP-1 
(present in plasmodium) and circulate in blood stream. CD35 is a 
cell surface receptor and its gene present in chromosome no. 1. It 
is also known as Complement Receptor Type 1 (CR1). Density of  
CD35, in cell surface is determined by CR1 gene polymorphism. 
There are types of  CR1 polymorphism (a) Structural polymor-
phism (b) density polymorphism (c) knops polymorphism. High 
density of  CD35 is more susceptible to plasmodium infection. 
ICAM-1 and VCAM-1 are also play important role in malarial 
pathogenesis. Cytokine profiling indicate malarial severity. Pro-in-
flammatory cytokine TNF-α and INF- γ level is increased during 
malarial infection where as IL10, IL4, and IL6 are anti-inflamma-
tory cytokine.
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